An ongoing dialogue on HIV/AIDS, infectious diseases,
July 11th, 2008
M184V: So many options, but does that include TDF/FTC/EFV?
Co-formulated TDF/FTC/EFV (Atripla) is a nifty bit of pharmacologic packaging (ever so much more so since it involves collaboration between two different pharmaceutical companies, ahem) — and our patients have noticed. All of us who practice HIV medicine have been asked for the “one pill” treatment; often these requests make sense, sometimes they don’t.
It’s easy to say when it’s a bad idea (known NNRTI resistance, for example), but sometimes it’s not so clear.
We presented a case in AIDS Clinical Care of someone with documented M184V several years previously (before a treatment interruption) who now needed to go back on treatment. Her request: the “one pill” treatment. One of our clinical experts (Joel Gallant) said he wouldn’t do it; the other (Jose Arribas) said he would. Not surprisingly, there were good reasons provided by both for their decisions.
We also asked if they’d order a viral tropism test. Joel — no. Jose — yes.
Thoughts? What do you do for patients who only have M184V?
Categories: Antiretroviral Rounds, HIV, Infectious Diseases, Patient Care
Tags: Atripla, M184V, TDF/FTC/EFV
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
4 Responses to “M184V: So many options, but does that include TDF/FTC/EFV?”
Paul E. Sax, MD
Contributing Editor
NEJM Journal Watch
Infectious Diseases
Biography | Disclosures | Summaries
Learn more about HIV and ID Observations.
Follow HIV and ID Observations Posts via Email
- Why We Have Antibiotic Shortages and Price Hikes — And What One Very Enterprising Doctor Did in Response
- Brave New Name — How PCP Became PJP and Why It Matters
- The Riveting Conclusion of How PCP Became PJP
- How Electronic Health Records Tyrannize Doctors — ID Doctors in Particular
- Learning the Names of HIV Drugs Is Horribly Difficult — Here’s Why
- ID Cartoon Caption Contest (125)
- ID Cartoon Caption Contest #2 Winner — and a New Contest for the Holidays (92)
- Dear Nation — A Series of Apologies on COVID-19 (80)
- How to Induce Rage in a Doctor (77)
- IDSA’s COVID-19 Treatment Guidelines Highlight Difficulty of “Don’t Just Do Something, Stand There” (74)
-
NEJM Journal Watch — Recent Infectious Disease Articles
- Rising Rates of Perinatal HIV: Maryland, 2022
- Do Children Need a Booster of Typhoid Conjugate Vaccine?
- Infection with Tecovirimat-Resistant Mpox Virus Is on the Rise in the U.S.
- Kidney Transplantation: Offering HOPE for Those with HIV
- Observations from ID and Beyond: Brave New Name — How PCP Became PJP and Why It Matters
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease MRSA PEP Policy PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster
What about treating her once daily with Atripla + Ziagen —
Would adding abacavir give her the necessary “third drug” in this case and allow her to use Atripla as she desires?
Would the 184V affect the efficacy of the abacavir too much to make it worthwhile?
I would check the hl b 5701 and the trofle assay. If the b 5701 was negative, I would offer her atripla and ziagen. If positive, I would explore twice-daily regimens with her, including isentress, intelence and selzentry as possibilities.
I like Dr. Gallant’s response of ritonavir-boosted PI with tenofovir/FTC even with the M184V. However, instead of a “two-drug regimen,” I would call it a “two and 1/2 drug regimen,” and it makes a lot of sense to me. Perhaps more patients could benefit from this simple regimen.
I would urge the patient to restart therapy using a boosted protease inhibitor based regimen that would be simple (once a day) and relatively fat friendly (such as ritonavir/fosamprenavir or ritonavir/atazanavir or ritonavir/darunavir + Truvada or Epzicom -the latter if HLA B5701 negative). I would be tempted (if the patient was willing) to initially recommend use of another agent (such as raltegravir) to rapidly suppress HIV RNA levels to the detection level and then stop it out of concern about the presence of more extensive NRTI resistance than detected by the genotypic results available and not wanting to use potential monotherapy (just a boosted PI) in a treatment experienced patient with underlying NRTI resistance.